In lung cancer treatment, preclinical study has suggested that CSF1R inhibition by BLZ945, a CSF1R inhibitor, substantially limits malignant pleural effusion formation induced by lung adenocarcinoma (92). Here, CSF1R is linked to lung carcinoma.